28 results about "Endometrosis" patented technology

The invention discloses pyruvate carboxylase (PC) serving as a biomarker for detecting endometriosis and application of the pyruvate carboxylase (PC) to treatment of the endometriosis. The biomarker can be used for detecting the expression level of PC in an endometrial tissue sample through an immunohistochemical method, and when the IHC score is greater than or equal to 4, a subject is judged to be at a high risk of endometriosis or suffered from the endometriosis. Meanwhile, the invention provides an application of drugs (including specific siRNA, ZY-444, octyl gallate and the like) for inhibiting PC expression in treatment of endometriosis, and a corresponding treatment method. The invention provides a new biomarker, target spot and scheme for detection and treatment of endometriosis, and has important clinical application value.

This invention belongs to the field of biomedicine and specifically relates to the use of β-hydroxybutyrate in the preparation of a drug for the treatment of endometriosis. In animal experiments, BHB treatment significantly reduced endometriosis lesions between days 4 to 18 and 28 after modeling. Clinical studies have also found decreased serum BHB levels in endometriosis patients, suggesting that BHB supplementation may improve endometriosis symptoms. This suggests that BHB has a beneficial therapeutic effect on endometriosis and holds promise for clinical application.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

This invention discloses the application of platelet-reactive protein-4 (THBS4) in the diagnosis and treatment of endometriosis. Through bioinformatics integration analysis, clinical sample validation, and in vitro and in vivo experiments, this invention confirms that THBS4 is significantly highly expressed in both ectopic lesions and peripheral blood of patients with endometriosis, and its expression level is positively correlated with disease severity. The area under the receiver operating characteristic (AUC) curve for THBS4 alone in diagnosing endometriosis is 0.930, significantly superior to cancer antigen 125 (CA125); the AUC for the combined diagnosis of THBS4 and CA125 reaches 0.968. Simultaneously, silencing the THBS4 gene effectively inhibits the proliferation, migration, and invasion of human endometrial stromal cells, and significantly reduces the volume and fibrosis area of ​​ectopic lesions in a mouse model of endometriosis. This invention provides a highly sensitive and specific new biomarker for the non-invasive or minimally invasive early diagnosis of endometriosis, and provides new targets and candidate drugs for non-hormone-dependent targeted therapy.

Provided are a collection medium and uses thereof for preventing menstrual blood clotting and preserving cell viability in menstrual blood samples. Also provided are methods of using such collection medium for finding novel and potentially diagnostic and prognostic biomarkers in menstrual blood for different gynecological disease such as endometriosis, gynecological cancers, and other non-reproductive diseases. Also included are methods for employing a dye test for distinguishing between living and dead cells in a sample.

The invention relates to an application of a NeuMME subgroup in preparation of a diagnostic kit for evaluating NETosis occurrence degree or endometriosis severity. The invention also provides an application of the NETosis inhibitor or the DNase I in preparation of a medicine for treating endometriosis. It is proved that NETs in the abdominal cavity promote colonization, migration and proliferation capacity of endometrial cells through the capture effect, so that occurrence and development of endometriosis focuses are promoted, the NeuMME subgroup is a main source of the NETs, and therefore detection of the NeuMME subgroup and evaluation of the occurrence degree of NETosis have important significance. In addition, based on clinical sample analysis, it is found that NeuMME subgroups of peritoneal fluid are closely related to clinical rASRM scores of endometriosis; the analysis of a mouse endometriosis model also finds that the NeuMME subgroup is closely related to the occurrence and development of an endometriosis focus. Therefore, the NeuMME-based subgroup detection for evaluating the severity of endometriosis and the focus progress has remarkable advantages and application prospects. The development of endometriosis can be remarkably inhibited by inhibiting NETosis or clearing NETs in a mouse model through a drug.

The invention discloses application of C3 and / or C3a and / or C3aR as a target spot in preparation of a preparation for diagnosing and / or treating diseases related to endometriosis, relates to the technical field of biological medicines, and provides application of C3 and / or C3a and / or C3aR as a target spot in preparation of a preparation for diagnosing and / or treating diseases related to endometriosis. The endometriosis comprises a uterus-sacral ligament type endometriosis, a peritoneal type endometriosis, a rectum-vagina type endometriosis, a deep infiltration type endometriosis, an ovarian type endometriosis, an abdominal wall incision type endometriosis, a perineum incision type endometriosis and a lung type endometriosis; and at least one of nasal endometriosis. The endometriosis can be diagnosed by detecting the content of at least one of C3, C3a and C3aR; the C3 and / or C3a and / or C3aR inhibitor can be used for reducing the focus and treating the endometriosis.

Methods and medicaments are provided for treating endometriosis in a subject in need thereof, the method comprising administering to the subject an effective amount of a sphingosine-1-phosphate receptor 1 (S1PR1)-antagonist.

Provided are a collection medium and uses thereof for preventing menstrual blood clotting and preserving cell viability in menstrual blood samples. Also provided are methods of using such collection medium for finding novel and potentially diagnostic and prognostic biomarkers in menstrual blood for different gynecological disease such as endometriosis, gynecological cancers, and other non-reproductive diseases. Also included are methods for employing a dye test for distinguishing between living and dead cells in a sample.

The invention belongs to the technical field of biological medicines, and particularly relates to application of beta-hydroxybutyric acid in preparation of a medicine for treating endometriosis. In animal experiments, in D4-D18 and D4-D28 periods after molding, the endometriosis focus can be obviously reduced through BHB treatment; clinical research finds that the BHB in serum of a patient with endometriosis is reduced, and the condition of endometriosis is expected to be improved by supplementing the BHB, so that the BHB has a good treatment effect on the endometriosis and has a good clinical application prospect.

The invention discloses an application of lysopc16: 0 and / or PPAR gamma and / or phospholipase A2 as a target spot in preparation of an endometriosis related treatment preparation, relates to the technical field of biological medicines, and provides an application of lysopc16: 0 and / or PPAR gamma and / or phospholipase A2 as a target spot in preparation of an endometriosis related treatment preparation. The invention relates to application of an inhibitor of lysopc16: 0 and / or PPAR gamma and / or phospholipase A2 in preparation of a medicine for treating endometriosis. The inhibitor is a PPAR (peroxisome proliferator activated receptor) gamma antagonist for blocking a lysopc16: 0 mediated PPAR gamma signal channel. The PPARgamma antagonist comprises GW9662, T0070907, MM902 and SR1664, and the PPARgamma antagonist comprises GW9662, T0070907, MM902 and The diagnosis accuracy of the endometriosis is improved through the target point of the lysopc16: 0, and the inhibitor of the lysopc16: 0 and / or the PPAR gamma and / or the phospholipase A2 can be used in the medicine for treating the endometriosis.

This invention belongs to the field of biotechnology, and particularly relates to the use of the SPON2 gene or its protein as a target in the diagnosis or treatment of endometriosis. Supported by multi-omics and single-cell level data and tested with clinical samples, this invention, for the first time, elucidates the correlation between SPON2 and endometriosis (EM), revealing that high expression of SPON2 in eutopic and ectopic endometrial fibroblasts in endometriosis patients enhances their proliferation, invasion, and migration abilities. Inhibiting SPON2 gene expression or inhibiting SPON2 protein function reduces the proliferation and invasion abilities of endometrial tissue, as well as lesion migration, invasion, and fibrosis, thus improving the condition of endometriosis. This suggests that the SPON2 gene or its protein can serve as a diagnostic or therapeutic target, providing new ideas and directions for the clinical diagnosis and targeted therapy of endometriosis.

The invention discloses application of hyperoside to treatment of endometriosis, and aims to evaluate whether hyperoside has an anti-fibrosis effect when applied to a rat endometriosis model by taking fibrosis as a treatment target. The method comprises the following steps: constructing a rat endometriosis model through an autotransplantation method, dividing molded rats into a low-dose group, a medium-dose group, a high-dose group, a model group and a western medicine control group 4 weeks after successful modeling, and laparotomizing and taking out ectopic lesions after respectively taking medicines for 4 weeks. HE staining and masson staining methods are used for mutually proving the fibrosis degree, the expression conditions of fibrosis indexes a-SMA, Co-1, CTGF and Fn are detected in an immunohistochemical mode, and the anti-fibrosis effect of hyperoside is evaluated. As a result, hyperoside can prevent the development of fibrosis in endometriosis, and thus hyperoside can be used as a drug for treating or preventing fibrosis in endometriosis.

The present invention provides a method of diagnosing endometriosis and / or infertility in a subject, comprising: a) obtaining a sample from the subject; b) detecting a level of expression of a SIRT1 gene and / or protein in the sample; c) detecting a level of expression of a BCL6 gene and / or protein in the sample; d) comparing the level of expression detected in (b) with the level of expression of a SIRT1 gene and / or protein in a sample obtained from a control subject or a population of control subjects; e) comparing the level of expression detected in (c) with the level of expression of a BCL6 gene and / or protein in a sample obtained from a control subject or a population of control subjects; and f) diagnosing the subject as having infertility when the subject has a level of expression of the SIRT1 gene and / or protein greater than the level of expression of the SIRT1 gene and / or protein of the control subject or population of control subjects and also has a level of expression of the BCL6 gene and / or protein that is greater than the level of expression of the BCL6 gene and / or protein of the control subject or population of control subjects.

The invention discloses an endometriosis brain function connection recognition method based on staging driving, which breaks through the limitation that a traditional model cannot describe a central regulation mechanism from a disease state through a brain function feedback recognition path taking an rASRM staging state as a driving variable, and also has the advantages of being simple in structure, convenient to operate and high in practicability. Through systematic comparison of the feedback connection modes in different staging states, the central feedback signal dependent on each staging stage is clearly identified, and an explanation basis is provided for association between endometriosis clinical typing and central symptom expression.

To provide methods for diagnosing endometriosis or determining whether or not a subject has endometriosis, methods for determining the degree of fibrosis or adhesions in the endometrium of a subject with endometriosis, methods for predicting pain in a subject with endometriosis, methods for monitoring the pathological condition of a subject with endometriosis, etc., and kits for performing these methods. [Solution] We found that there are multiple markers present in endometriosis patients that differ in quantity from those present in healthy individuals, and that by measuring the amount of these markers, it is possible to diagnose whether or not a subject has endometriosis, determine the degree of endometrial fibrosis and adhesions, predict pain in subjects with endometriosis, and monitor the pathological condition of subjects with endometriosis.

Provided herein are methods for treating endometriosis in a subject, said methods comprising the administration of an effective amount of an agent that inhibits CGRP / RAMP1 signaling to a subject in need thereof. Administration of an agent that inhibits CGRP / RAMP1 signaling may result in a reduction of pain associated with endometriosis in the subject, and / or a reduction of endometrial lesion size.

In general, the present disclosure describes a computer-implemented method that can be used to detect at least one sign of endometriosis (e.g., a Douglas pouch (POD) closure), as well as a solution to the modality missing problem. Advantageously, the method of the present technology can accurately classify at least one sign of endometriosis using TVUS or MRI data, thereby indicating a diagnosis of endometriosis in a patient.

This invention discloses the application of the compound pimozide in combination with metronidazole in the preparation of a drug for improving oocyte quality and treating endometriosis-related fertility disorders, belonging to the field of biomedical technology. The efficacy of this invention was verified by constructing mouse models of endometriosis driven by pathogenic *Prevotella bisporus* and mouse models of ovarian endometriosis. Experimental results showed that the combined administration significantly eliminated *Prevotella bisporus* colonizing ectopic lesions, reduced succinic acid content in both eutopic and ectopic lesions, decreased the succinylation level of lysine residue 195 of the ACADVL protein, reduced the fluidity of primary endometrial epithelial cell membranes, reduced the volume and weight of endometriotic lesions, and improved oocyte spermatogenesis, ovulation rate, and litter size. This invention solves the problem that existing therapies cannot simultaneously control endometriosis lesions and protect reproductive function, providing a new, safe, and effective combined treatment option for patients with endometriosis and infertility.

Disclosed herein is a pharmaceutical composition for preventing or treating endometriosis, comprising fraxetin. When used as a pharmaceutical composition for preventing or treating endometriosis and complications associated therewith, with fraxetin or a pharmaceutically acceptable salt thereof as an active ingredient, the present disclosure offers effective management of endometriosis with fewer side effects compared to surgery and hormone therapy and thus can be advantageously used as a therapeutic agent for endometriosis and complications associated therewith.

This invention pertains to the clinical application of traditional Chinese medicine, primarily focusing on the application of a Chinese herbal extract in the prevention and treatment of endometriosis. The invention also relates to a method for preparing this extract. The preparation method involves: taking 250 g of raw Curcuma zedoaria slices and heating them under reflux with 15 times the volume of 90% ethanol, extracting twice, 1.5 h each time; then extracting the residue with 10 times the volume of distilled water for 1.5 h; combining the ethanol and water extracts, filtering, and concentrating under reduced pressure at 55°C to a crude drug content of 1.93 g / mL. In vivo experiments have demonstrated that the extract significantly reduces the volume of ectopic endometrium. HE staining in nude mice in the endometrial lesion group revealed extensive inflammatory infiltration and angiogenesis in the ectopic endometrial lesions. Administration of the extract significantly reduced inflammatory infiltration and angiogenesis. Immunohistochemical staining of nude mice in the EMs group revealed high positive rates of PCNA and MVD cells. After administration of the herbal extract of this invention, the positive rates of PCNA and MVD cells were significantly reduced, demonstrating a significant anti-endometriosis effect.

Provided herein are peptides that bind to beta-catenin and compositions comprising the peptides. Agents utilizing peptides that bind directly to beta-catenin can be used for imaging, diagnosis, and therapeutic purposes of diseases driven by beta-catenin dysfunction. Also provided herein are methods of using the peptides and compositions in the imaging, diagnosis, and treatment of tissue infiltrating conditions, including endometriosis.

The invention discloses a traditional Chinese medicine composition for dispersing blood stasis and eliminating stagnation and application of the traditional Chinese medicine composition in preparation of a medicine for treating endometriosis, and belongs to the technical field of traditional Chinese medicine pharmacy. The composition is formed by scientific compatibility of multiple traditional Chinese medicinal materials, the formula is rigorous, all the components have a synergistic effect, and the effects of dispersing blood stasis, eliminating stagnation, resisting inflammation, easing pain and inhibiting ectopic focus hyperplasia can be achieved. Animal tests and clinical researches prove that the composition can effectively reduce the volume of ectopic lesions, reduce the level of inflammatory factors, relieve dysmenorrhea and improve traditional Chinese medicine syndromes, the clinical total effective rate reaches 92.5%, no obvious toxic or side effect exists in medication, existing clinical treatment defects are overcome, a novel safe and efficient traditional Chinese medicine treatment scheme is provided for endometriosis, and the composition is worthy of popularization and application. The clinical application value is relatively high.

The invention belongs to the technical field of biology, and particularly relates to application of an SPON2 gene or a protein thereof as a target spot in diagnosis or treatment of endometriosis. Through multi-omics and single cell level data support and clinical sample inspection, the correlation between SPON2 and endometriosis (EM) is analyzed for the first time, and it is revealed that proliferation, invasion and migration capacities of in-situ endometrial and ectopic endometrial fibroblasts of endometriosis patients can be enhanced through high expression of SPON2. By inhibiting the expression of the SPON2 gene or inhibiting the function of the SPON2 protein, the proliferation and invasion ability of endometrial tissues and the migration, invasion and fibrosis of lesions are reduced, and the condition of endometriosis is improved, which prompts that the SPON2 gene or the protein thereof can be used as a diagnosis or treatment target. And a new thought and direction are provided for clinical diagnosis and targeted therapy of endometriosis.

The application relates to an endometriosis causal gene screening method and device based on cross-brain region genetic regulation integration analysis, equipment and a medium, and relates to the technical field of biomedical testing. The method constructs a cross-system genetic analysis platform, realizes a reproducible cross-tissue genetic integration analysis framework by integrating brain region eQTL data and large sample GWAS statistical results, and comprises the following steps: identifying a potential pathogenic path and a candidate causal gene of central expression factors by using eQTL data and GWAS data, covering data acquisition, tool variable construction, causal inference modeling, linkage disequilibrium control and functional annotation analysis, realizing cross-system analysis of a genetic regulation mechanism of an endometriosis pathogenic risk, and focusing on exploring a remote action path of brain region homeostatic expression on disease susceptibility.

The present invention relates to methods of assessing whether a patient has endometriosis or is at risk of developing endometriosis, to methods of selecting a patient for therapy, and method of monitoring a patient suffering from endometriosis or being treated for endometriosis by determining the amount or concentration of S100A8 in a sample of the patient, and comparing the determined amount or concentration to a reference.

The invention belongs to the technical field of medicines, and particularly relates to application of a reagent for inhibiting EZH2 protein phosphorylation in preparation of a medicine for treating endometriosis, and EZH2 protein phosphorylation refers to threonine phosphorylation at the 345th site of EZH2 protein. Through phosphorylated proteomics screening and functional verification, threonine at the 345th site of the EZH2 protein is determined as a downstream key target of DUSP5 through phosphorylation for the first time. By utilizing an EZH2 T345D mutant simulating continuous phosphorylation, it is directly proved that the activity of pT345-EZH2 is a sufficient condition for driving macrophages to be polarized to the M2 phenotype, it is proved that the activity of pT345-EZH2 promotes the macrophages to be polarized to the M2 phenotype, and then development of endometriosis is promoted. And a solid data support and a clear scientific basis are provided for promoting the pT345-EZH2 to drug research and development.

The invention provides a construction method used for researching endometriosis. The method comprises the following steps: transplanting human ovary-derived ectopic endometrial tissues into an immunodeficient animal body, and additionally adding estrogen for local stimulation, so as to construct a subcutaneous endometriosis xenotransplantation model. The method has the advantages that: 1, tissues are derived from a human body, and an enzyme system and a drug target are both derived from the human body; 2, the transplanted ectopic endometrial tissue has the characteristics of structural disorder and mixing of glands and interstitial substances, and is highly close to the disease state of a human body; 3, subcutaneous transplantation operation is simple, observation is direct, and intervention is convenient; 4, local estrogen stimulation simulates a high-estrogen environment of ectopic intima, so that the survival rate and the survival time of the graft are improved. Test results show that the graft locally injected with estradiol is high in survival rate after being transplanted for 30 days, the structure is kept compact, the living cell form is complete, and the graft is closer to the original tissue. The model is closer to the pathological characteristics of human endometriosis, and a more ideal platform is provided for pathogenesis research and drug development.